The Food and Drug Administration has alerted the public that the agency is currently reviewing all available information on the potential for increased risk of new malignancies associated with lenalidomide in patients treated for multiple myeloma or myelodysplatic syndromes.The agency plans to communicate any new recommendations once it has completed its review of existing data, according to a safety announcement released on April 8, 2011. "At this time, [the] FDA recommends that patients continue...